Warning! GuruFocus detected
2 Severe warning signs
with 3O8.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Omeros Corp
NAICS : 325412
SIC : 2834
ISIN : US6821431029
Share Class Description:
FRA:3O8: Ordinary SharesDescription
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.59 | |||||
| Equity-to-Asset | -0.49 | |||||
| Debt-to-Equity | -1.36 | |||||
| Debt-to-EBITDA | -1.34 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 8.1 | |||||
| 3-Year EPS without NRI Growth Rate | -0.5 | |||||
| 3-Year Book Growth Rate | 40.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.49 | |||||
| 9-Day RSI | 41.43 | |||||
| 14-Day RSI | 43.85 | |||||
| 3-1 Month Momentum % | -27.44 | |||||
| 6-1 Month Momentum % | 129.44 | |||||
| 12-1 Month Momentum % | 156.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.96 | |||||
| Quick Ratio | 2.96 | |||||
| Cash Ratio | 2.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 26.43 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -34 | |||||
| ROIC % | -87.03 | |||||
| 3-Year ROIIC % | -18.19 | |||||
| ROC (Joel Greenblatt) % | -799.23 | |||||
| ROCE % | -48.89 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -3.58 | |||||
| EV-to-Forward-EBIT | -0.6 | |||||
| EV-to-EBITDA | -3.6 | |||||
| EV-to-Forward-EBITDA | -0.6 | |||||
| EV-to-Forward-Revenue | 13.29 | |||||
| EV-to-FCF | -3.73 | |||||
| Earnings Yield (Greenblatt) % | -27.93 | |||||
| FCF Yield % | -32.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Omeros Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.124 | ||
| Beta | 2.76 | ||
| 3-Year Sharpe Ratio | 0.58 | ||
| 3-Year Sortino Ratio | 1.44 | ||
| Volatility % | 197.99 | ||
| 14-Day RSI | 43.85 | ||
| 14-Day ATR (€) | 0.400563 | ||
| 20-Day SMA (€) | 7.67 | ||
| 12-1 Month Momentum % | 156.99 | ||
| 52-Week Range (€) | 2.516 - 12.39 | ||
| Shares Outstanding (Mil) | 57.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Omeros Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Omeros Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Omeros Corp Frequently Asked Questions
What is Omeros Corp(FRA:3O8)'s stock price today?
The current price of FRA:3O8 is €7.53. The 52 week high of FRA:3O8 is €12.39 and 52 week low is €2.52.
When is next earnings date of Omeros Corp(FRA:3O8)?
The next earnings date of Omeros Corp(FRA:3O8) is 2025-05-15 Est..
Does Omeros Corp(FRA:3O8) pay dividends? If so, how much?
Omeros Corp(FRA:3O8) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers